Legal & General Group
IPXL

Legal & General Group’s Impax Laboratories, Inc. IPXL Stock Holding History

Legal & General Group’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-151,134
Closed -$2.94M – 3462
2018
Q1 		$2.94M Buy
151,134
+2,275
+2% +$44.6K ﹤0.01% 1403
2017
Q4 		$2.48M Buy
148,859
+440
+0.3% +$8.06K ﹤0.01% 1504
2017
Q3 		$3.02M Buy
148,419
+5,967
+4% +$114K ﹤0.01% 1345
2017
Q2 		$2.29M Buy
142,452
+10,618
+8% +$157K ﹤0.01% 1452
2017
Q1 		$1.67M Buy
131,834
+610
+0.5% +$7.37K ﹤0.01% 1576
2016
Q4 		$1.74M Buy
131,224
+64,178
+96% +$1.1M ﹤0.01% 1495
2016
Q3 		$1.59M Buy
67,046
+51,324
+326% +$1.38M ﹤0.01% 1188
2016
Q2 		$453K Hold
15,722
– – ﹤0.01% 1373
2016
Q1 		$502K Buy
15,722
+1,481
+10% +$52.1K ﹤0.01% 1312
2015
Q4 		$613K Buy
14,241
+684
+5% +$27.3K ﹤0.01% 1276
2015
Q3 		$466K Buy
13,557
+572
+4% +$25.8K ﹤0.01% 1318
2015
Q2 		$596K Buy
12,985
+488
+4% +$23.2K ﹤0.01% 1272
2015
Q1 		$584K Buy
12,497
+2,322
+23% +$92.4K ﹤0.01% 1246
2014
Q4 		$326K Sell
10,175
-212
-2% -$6.2K ﹤0.01% 1354
2014
Q3 		$251K Buy
+10,387
New +$266K ﹤0.01% 1400

Legal & General Group's IPXL Position: Q2 2018 in Review

Legal & General Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 151,134 shares — an estimated $2.94M sold.

Legal & General Group first reported a position in IPXL in Q3 2014 and held it in 15 quarters. The position peaked at $3.02M in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

  • Legal & General Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 151,134 Impax Laboratories, Inc. shares in Q2 2018, an estimated $2.94M.
  • Legal & General Group first reported a position in Impax Laboratories, Inc. in Q3 2014 and held it in 15 quarters.
  • Legal & General Group's Impax Laboratories, Inc. position peaked at $3.02M in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.